Interpretation of the evidence for the efficacy and safety of statin therapy

@article{Collins2016InterpretationOT,
  title={Interpretation of the evidence for the efficacy and safety of statin therapy},
  author={Rory Collins and C Reith and Jonathan R. Emberson and Jane Armitage and Colin Baigent and Lisa Blackwell and Roger S. Blumenthal and John Danesh and George Davey Smith and David L DeMets and Stephen Evans and Malcolm R Law and Stephen MacMahon and Seth Shay Martin and Bruce Neal and Neil R. Poulter and David Preiss and Paul M. Ridker and Ian W. Roberts and Anthony Rodgers and Peter A. G. Sandercock and Kenneth F. Schulz and Peter Sever and John R. Simes and Liam Smeeth and Nicholas J. Wald and Salim Yusuf and Richard Peto},
  journal={The Lancet},
  year={2016},
  volume={388},
  pages={2532-2561}
}

Figures and Tables from this paper

Dyslipidaemia: Balancing the benefits and risks of statin therapy
“The numbers of people who avoid heart attacks and strokes by taking statin therapy are very much larger than the numbers who have side effects with it,” claims Rory Collins, lead author of a Review
Statin Safety: What Every Health Care Provider Needs to Know
TLDR
Large-scale randomized evidence indicates that a small increase in myopathy, diabetes, and hemorrhagic stroke may occur with statin Therapy, but these adverse effects are greatly outweighed by the cardiovascular benefit of statin therapy.
Evidence-based goals in LDL-C reduction
TLDR
Recent safety and efficacy data from trials of adjunctive therapy, with LDL-C lowering beyond that achieved by statin therapy, and their potential implications for current guideline targets are reviewed.
Recent flaws in Evidence Based Medicine: statin effects in primary prevention and consequences of suspending the treatment.
TLDR
It is concluded that despite the recent hype raised by HOPE-3, the cholesterol-lowering rosuvastatin is likely not beneficial in intermediate-risk individuals without cardiovascular disease (primary prevention), and this trial may even represent a typical example of how evidence-based medicine has been flawed in commercial studies.
Safety and efficacy of statin therapy
TLDR
Although hepatotoxicity has been a previous concern when using statin therapy, data suggest that statins are safe and that levels of liver enzymes do not need to be checked routinely and data from trials on PCSK9 inhibitors suggest that low LDL-cholesterol levels are safe.
Statin use and risk for type 2 diabetes: what clinicians should know
TLDR
The data from RCTs and observational studies for statin-associated T2D risk are summarized, and the risk-benefit ratio still strongly favors use of statin therapy, or intensive statin Therapy, for patients with sufficient CV disease risk to warrant cholesterol-lowering drug therapy.
Evidence for more intensive cholesterol lowering
TLDR
A meta-analysis of all randomized controlled trials with CVD end-points concludes that when initial LDL cholesterol exceeds 4’mmol/l and absolute CVD risk demands it, a target value of 1.8 mmol /l should be achieved, if necessary by adding ezetimibe and/or PCSK9 inhibitors to statin treatment.
Medicalisation, risk and the use of statins for primary prevention of cardiovascular disease: a scoping review of the literature
TLDR
It was found that few studies differentiated between the use of statins in those with and those without established cardiovascular disease, despite the fact that the majority of statin users, and women in particular, fall into the primary prevention category.
The Role of Statins in Current Guidelines
The causal association of LDL-cholesterol (LDL-C) with atherosclerotic cardiovascular disease (ASCVD) has been demonstrated in robust experimental, epidemiological, genetic, and interventional
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 414 REFERENCES
Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment.
TLDR
These problems can be overcome by basing the decision to treat on the NNT calculated both from absolute CVD risk and also on the LDL (or non-HDL) cholesterol reduction achievable with statin treatment, thus permitting more effective deployment of statins in the population.
Statin tolerability: In defence of placebo-controlled trials
TLDR
It appears that statin intolerance in the clinic is commonly due to the nocebo effect causing patients to attribute background symptoms to the statin, and over 90% of patients who have stopped treatment because of an adverse event can tolerate a statin if re-challenged.
Should there be a moratorium on the use of cholesterol lowering drugs?
TLDR
An aggressive approach to cholesterol reduction features in most of the official guidelines for the primary prevention of coronary heart disease, and high percentages of the British population would become candidates for drug treatment if the guidelines currently advanced by some authorities were put into practice.
Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis.
TLDR
Statin therapy is an effective intervention in the secondary prevention of cardiovascular events in both sexes, but there is no benefit on stroke and all-cause mortality in women.
Risks Associated with Statin Therapy: A Systematic Overview of Randomized Clinical Trials: P113
Background— Although statins reduce the risk of cardiovascular events, concerns about adverse effects may deter physicians from prescribing these agents. We performed a systematic overview of
Statin intolerance: reconciling clinical trials and clinical experience.
TLDR
A frequent objection to reliance on the trials of outcomes with statins is that trials exclude many patients who would be prescribed a statin in clinical practice, and this is attempted to account for and explain the discrepancy between clinical trials and clinical practice.
Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy
TLDR
Statin treatment for 5 years was associated with a legacy benefit, with improved survival and a substantial reduction in cardiovascular disease outcomes over a 20-year period, supporting the wider adoption of primary prevention strategies.
...
1
2
3
4
5
...